Cargando…

Pembrolizumab-related Immune Thrombocytopenia in a Patient with Lung Adenocarcinoma Treated by Radiotherapy: Potential Immune-related Adverse Event Elicited by Radiation Therapy

The effect of radiotherapy during immunotherapy on immune-related adverse events (irAEs) is not fully understood. We herein report a 74-year-old woman diagnosed with lung adenocarcinoma with programmed death ligand 1 expression ≥50% and treated with pembrolizumab. She developed fatal immune thromboc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tamanoi, Daisuke, Saruwatari, Koichi, Imamura, Kosuke, Sato, Ryo, Jodai, Takuya, Hamada, Shohei, Tomita, Yusuke, Saeki, Sho, Ueno, Shikiko, Yonemura, Yuji, Ichiyasu, Hidenori, Sakagami, Takuro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259326/ https://www.ncbi.nlm.nih.gov/pubmed/34776479 http://dx.doi.org/10.2169/internalmedicine.7581-21

Ejemplares similares

Primary lung sebaceous carcinoma successfully treated with radiotherapy and pembrolizumab: A case report
por: Jodai, Yasumiko, et al.
Publicado: (2022)

Non-small-cell Lung Cancer with Severe Skin Manifestations Related to Radiation Recall Dermatitis after Atezolizumab Treatment
por: Nakashima, Kei, et al.
Publicado: (2020)

Airway Pseudomonas aeruginosa density in mechanically ventilated patients: clinical impact and relation to therapeutic efficacy of antibiotics
por: Migiyama, Yohei, et al.
Publicado: (2021)

Clostridium butyricum therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors
por: Tomita, Yusuke, et al.
Publicado: (2022)

A potential mechanism of the onset of acute eosinophilic pneumonia triggered by an anti‐PD‐1 immune checkpoint antibody in a lung cancer patient
por: Jodai, Takayuki, et al.
Publicado: (2018)

The Risks and Benefits of Immune Checkpoint Blockade in Anti-AChR Antibody-Seropositive Non-Small Cell Lung Cancer Patients
por: Saruwatari, Koichi, et al.
Publicado: (2019)

Small Cell Lung Cancer Derived from Adenocarcinoma with Mutant Epidermal Growth Factor Receptor Provides a Signature of Transcriptional Alteration in Tumor Cells
por: Tenjin, Yuki, et al.
Publicado: (2019)

Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies
por: Sato, Ryo, et al.
Publicado: (2019)

Clinical Implications and Molecular Characterization of Drebrin-Positive, Tumor-Infiltrating Exhausted T Cells in Lung Cancer
por: Imamura, Kosuke, et al.
Publicado: (2022)

Interstitial Lung Disease in Adulthood Associated with Surfactant Protein C Gene Mutation in a Patient with a History of Lipoid Pneumonia in Infancy
por: Furukawa, Tsuguhiro, et al.
Publicado: (2023)

Clinical impact of SUV(max) of interstitial lesions in lung cancer patients with interstitial lung disease who underwent pulmonary resection
por: Akaike, Kimitaka, et al.
Publicado: (2022)

Successful treatment with dupilumab for mucus plugs in severe asthma
por: Anai, Moriyasu, et al.
Publicado: (2022)

Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer
por: Hamada, Shohei, et al.
Publicado: (2019)

Heterogeneous Tumor-Immune Microenvironments between Primary and Metastatic Tumors in a Patient with ALK Rearrangement-Positive Large Cell Neuroendocrine Carcinoma
por: Tashiro, Takahiro, et al.
Publicado: (2020)

Heterogeneous tumor‐immune microenvironments between primary and metastatic carcinoid tumors differentially respond to anti‐PD‐L1 antibody therapy
por: Sakata, Shinya, et al.
Publicado: (2020)

(18)F‐FDG uptake in accessory respiratory muscles shows the respiratory effort of patients with pleuroparenchymal fibroelastosis
por: Okabayashi, Hiroko, et al.
Publicado: (2022)

Prognostic impact of pre-existing interstitial lung disease in non-HIV patients with Pneumocystis pneumonia
por: Hamada, Shohei, et al.
Publicado: (2020)

Validation of a breath-holding test as a screening test for exercise-induced hypoxemia in chronic respiratory diseases
por: Ideguchi, Hideharu, et al.
Publicado: (2021)

Pembrolizumab‐caused polyradiculoneuropathy as an immune‐related adverse event
por: Kurashige, Takashi, et al.
Publicado: (2021)

Acute exacerbation of chronic fibrosing interstitial pneumonia in patients receiving antifibrotic agents: incidence and risk factors from real-world experience
por: Kawamura, Kodai, et al.
Publicado: (2019)

IgA Nephropathy that Developed as an Immune-related Adverse Event of Pembrolizumab Complicated with Interstitial Nephritis
por: Mitarai, Yuki, et al.
Publicado: (2021)

Aseptic Meningitis as an Immune-Related Adverse Event after Pembrolizumab
por: Lima, Gian, et al.
Publicado: (2019)

Clinical effects of direct hemoperfusion using a polymyxin B-immobilized fiber column in clinically amyopathic dermatomyositis-associated rapidly progressive interstitial pneumonias
por: Okabayashi, Hiroko, et al.
Publicado: (2017)

Efficacy of direct hemoperfusion using polymyxin B-immobilized fiber column (PMX-DHP) in rapidly progressive interstitial pneumonias: results of a historical control study and a review of previous studies
por: Ichiyasu, Hidenori, et al.
Publicado: (2017)

Decrease in hemoglobin level predicts increased risk for severe respiratory failure in COVID-19 patients with pneumonia
por: Anai, Moriyasu, et al.
Publicado: (2021)

Unchecked immunity: a unique case of sequential immune-related adverse events with Pembrolizumab
por: Shah, N., et al.
Publicado: (2019)

Monocyte count and the risk for acute exacerbation of fibrosing interstitial lung disease: A retrospective cohort study
por: Kawamura, Kodai, et al.
Publicado: (2020)

Immune Checkpoint-Related Gene Polymorphisms Are Associated With Primary Immune Thrombocytopenia
por: Wang, Shuwen, et al.
Publicado: (2021)

A Case of Biphasic Pulmonary Blastoma Treated with Carboplatin and Paclitaxel plus Bevacizumab
por: Sakata, Shinya, et al.
Publicado: (2015)

Primary Diaphragmatic Dedifferentiated Liposarcoma in a Young Female Patient after Delivery
por: Sakata, Shinya, et al.
Publicado: (2016)

Elevated serum IgG4 levels in two cases of paragonimiasis
por: Saeki, Sho, et al.
Publicado: (2015)

TGFβ Signaling Activated by Cancer-Associated Fibroblasts Determines the Histological Signature of Lung Adenocarcinoma
por: Sato, Ryo, et al.
Publicado: (2021)

Hematological Side Effects of Immune Checkpoint Inhibitors: The Example of Immune-Related Thrombocytopenia
por: Calvo, Roser
Publicado: (2019)

SJS/TEN immune-related dermatologic reaction secondary to immune checkpoint inhibitor pembrolizumab in skin of color
por: Pierre, A.B., et al.
Publicado: (2023)

WHO, RECIST, and immune-related response criteria: is it time to revisit pembrolizumab results?
por: Ades, Felipe, et al.
Publicado: (2015)

Inflammation-Related Gene Polymorphisms Associated With Primary Immune Thrombocytopenia
por: Li, Ju, et al.
Publicado: (2017)

Management of COVID-19-related immune thrombocytopenia by rhTPO
por: Zhang, Xuzhao, et al.
Publicado: (2021)

No need to hesitate: immune‐related neutropenia and thrombocytopenia that improved by corticosteroids
por: Kanai, Osamu, et al.
Publicado: (2021)

Immune thrombocytopenia
Publicado: (2011)

Complete response in a patient with lung cancer suffering from three pembrolizumab‐induced immune‐related adverse events including retinal vasculitis
por: Mimura, Chihiro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bjp40hdgva91dob2s6mujs4t6p